文献速递泌尿生殖腹部MRUS

PI-RADS 2.0版与2.1版比较:从MRI靶向活检到根治性前列腺切除术的前列腺癌Gleason分级升级与降级率

PI-RADS Version 2.0 Versus Version 2.1: Comparison of Prostate Cancer Gleason Grade Upgrade and Downgrade Rates From MRI-Targeted Biopsy to Radical Prostatectomy.
PubMed 文献 · AJR Am J Roentgenol · 2023-09-20

该研究回顾性分析308例在前列腺MRI后行MRI/US融合靶向活检及根治性前列腺切除术的患者,比较PI-RADS v2.0(n=177)与v2.1(n=131)在ISUP分级组升级率和降级率上的差异。结果显示两组在升级率(29% vs 22%,p=.15)、降级率(19% vs 21%,p=.76)、临床显著升级率(14% vs 10%,p=.27)及临床显著降级率(1% vs 1%,p>.99)均无显著差异。结论认为PI-RADS更新未改善活检与手术之间的分级不一致性。

要点

  • PI-RADS v2.0与v2.1组间活检到根治术的ISUP分级升级率(29% vs 22%)和降级率(19% vs 21%)均无显著差异。
  • 临床显著升级率(14% vs 10%)和临床显著降级率(1% vs 1%)在两组间亦无显著差异。
  • 按指数病灶PI-RADS分类或分区分层后,两组升级率和降级率仍无显著差异(所有p>.01)。

核心结论

  • 使用PI-RADS v2.0或v2.1进行临床解读的患者,其从靶向活检到根治性前列腺切除术的ISUP分级升级率和降级率无显著差异。

研究设计与样本

  • 回顾性事后分析,纳入2015年5月至2023年3月单中心3T前列腺MRI后行MRI/US融合靶向活检及1年内根治性前列腺切除术的患者308例(v2.0组177例,v2.1组131例)。

诊断标准与关键数值

  • 临床显著癌定义为ISUP分级组≥2;v2.0组升级率29%、降级率19%、临床显著升级率14%、临床显著降级率1%;v2.1组分别为22%、21%、10%、1%。

临床应用与阅片要点

  • 在解读PI-RADS v2.0或v2.1时,应知晓两者在预测根治术ISUP分级升级或降级方面无显著差异。

局限性

  • 本研究为回顾性事后分析。
  • 研究在单中心进行。
  • MRI临床解读由单一泌尿生殖放射科医生完成。
  • v2.0和v2.1的解读时间段不同(2015年5月至2019年3月 vs 2019年4月至2023年3月)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND. Precise risk stratification through MRI/ultrasound (US) fusion-guided targeted biopsy (TBx) can guide optimal prostate cancer (PCa) management. OBJECTIVE. The purpose of this study was to compare PI-RADS version 2.0 (v2.0) and PI-RADS version 2.1 (v2.1) in terms of the rates of International Society of Urological Pathology (ISUP) grade group (GG) upgrade and downgrade from TBx to radical prostatectomy (RP). METHODS. This study entailed a retrospective post hoc analysis of patients who underwent 3-T prostate MRI at a single institution from May 2015 to March 2023 as part of three prospective clinical trials. Trial participants who underwent MRI followed by MRI/US fusion-guided TBx and RP within a 1-year interval were identified. A single genitourinary radiologist performed clinical interpretations of the MRI examinations using PI-RADS v2.0 from May 2015 to March 2019 and PI-RADS v2.1 from April 2019 to March 2023. Upgrade and downgrade rates from TBx to RP were compared using chi-square tests. Clinically significant cancer was defined as ISUP GG2 or greater. RESULTS. The final analysis included 308 patients (median age, 65 years; median PSA density, 0.16 ng/mL2). The v2.0 group (n = 177) and v2.1 group (n = 131) showed no significant difference in terms of upgrade rate (29% vs 22%, respectively; p = .15), downgrade rate (19% vs 21%, p = .76), clinically significant upgrade rate (14% vs 10%, p = .27), or clinically significant downgrade rate (1% vs 1%, p > .99). The upgrade rate and downgrade rate were also not significantly different between the v2.0 and v2.1 groups when stratifying by index lesion PI-RADS category or index lesion zone, as well as when assessed only in patients without a prior PCa diagnosis (all p > .01). Among patients with GG2 or GG3 at RP (n = 121 for v2.0; n = 103 for v2.1), the concordance rate between TBx and RP was not significantly different between the v2.0 and v2.1 groups (53% vs 57%, p = .51). CONCLUSION. Upgrade and downgrade rates from TBx to RP were not significantly different between patients whose MRI examinations were clinically interpreted using v2.0 or v2.1. CLINICAL IMPACT. Implementation of the most recent PI-RADS update did not improve the incongruence in PCa grade assessment between TBx and surgery.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Yilmaz EC, Lin Y, Belue MJ, et al. PI-RADS Version 2.0 Versus Version 2.1: Comparison of Prostate Cancer Gleason Grade Upgrade and Downgrade Rates From MRI-Targeted Biopsy to Radical Prostatectomy. AJR Am J Roentgenol. 2023. PMID: 37729551. doi:10.2214/AJR.23.29964

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。